Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.58 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.58 |
| ▸ | TFPI | P10646 | 1/20 | 0.57 |
| ▸ | CTSD | P07339 | 2/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8722013 | 0.97 | BACE1 (0.58) | BACE1BACE2TFPICTSDNPY1R | |
| SCHEMBL8722030 | 0.97 | BACE1 (0.58) | BACE1BACE2TFPICTSDNPY1R | |
| SCHEMBL31672193 | 0.93 | BACE1 (0.61) | BACE1BACE2TFPICTSD | |
| SCHEMBL29893268 | 0.91 | TFPI (0.60) | BACE1BACE2TFPICTSD | |
| SCHEMBL8742387 | 0.91 | BACE1 (0.60) | BACE1BACE2TFPICTSD | |
| SCHEMBL8742407 | 0.91 | BACE1 (0.60) | BACE1BACE2TFPICTSD | |
| SCHEMBL29810719 | 0.90 | TFPI (0.62) | BACE1BACE2TFPICTSD | |
| SCHEMBL31182826 | 0.89 | VIPR1 (0.59) | BACE1BACE2TFPINPY1RNPY4R | |
| SCHEMBL30262077 | 0.89 | TFPI (0.67) | BACE1BACE2TFPICTSD | |
| SCHEMBL29397483 | 0.89 | BACE1 (0.68) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12214043-B2 | Therapeutic nanomaterials | UNIVERSITY OF CONNECTICUT | 2025-02-04 | — | — | US | disclosed |
| WO-2023192975-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20220133893-A1 | Therapeutic Nanomaterials | UNIVERSITY OF CONNECTICUT | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | BACE1 4108/4885BACE2 4018/4885TFPI 2826/4885 |
| US-20220133893-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | BACE1 4108/4885BACE2 4018/4885TFPI 2826/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | BACE1 3673/4885BACE2 4530/4885TFPI 1021/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | BACE1 4235/4885BACE2 4757/4885TFPI 719/4885 |
| US-12214043-B2 | Therapeutic nanomaterials | TIE1, TEKT1, POLRMT | BACE1 4108/4885BACE2 4018/4885TFPI 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.